39 results about "Erythropoietin receptor" patented technology

Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed.

This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.

Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed.

The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin moiety as well as of the immunoglobulin moiety and the glycosylation pattern of erythropoietin fusion proteins with enhanced biological activity can be obtained. The invention relates also to novel nun-fused EPO molecules which have a pattern of cysteines or disulfide bonding which is distinct from human or animal EPO.

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

A E. coli recombinant plasmid expressing a fusion protein having the human erythropoietin receptor extracellular domain is disclosed. A purified fusion protein produced from such a vector is also disclosed, the fusion protein having a cleavage site suitable for separating the erythropoietin receptor extracellular domain from the remainder of the fusion protein. Antibodies having specific binding affinity for a purified extracellular domain polypeptide are also disclosed. The purified human erythropoietin receptor fragment polypeptide binds erythropoietin. The articles, compositions and methods of the invention are useful for studying ligand binding to erythropoietin receptor and for quantitating the amounts of erythropoietin receptor, as well as for understanding receptor structure and signal transduction.

The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer.

Compounds are provided that complex with the modulating domain of erythropoietin receptor (EPO-R) for use with EPO-R to determine the presence of EPO-R, the ability of other molecules to bind to the modulating domain in competitive assays and to induce a signal by EPO-R into a cell when bound by the subject compounds in a physiological environment. The compounds are characterized by having a six-membered heterocyclic ring comprising at least one nitrogen atom and include substituted triazolopyrimidine, pyridazinone, pyridine and piperidine.

Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.

An agent for prophylaxis or treatment of proliferative organ diseases, chronic arthritic diseases, hypertrophic scars or keloid, comprising an erythropoietin receptor antagonist or a salt thereof.

Methods and compositions are provided for protecting or enhancing the function or viability of effector cells, tissues, organs or body parts in mammals, including humans, in vivo, in situ or ex vivo, i.e. by systemic or local administration of recombinant tissue protective cells Factors such as modulators of erythropoietin receptor activity.

The invention discloses white rat IL-17RE membrane crossing area and inside cell area polypeptide and the coding sequence, fusion albumen and cell line. The polypeptide is one sequence of the following aminoacid residue: SEQ ID No:2, the albumen relative to cell transferring of SEQ ID No:1 that has been replaced and/or lacking and/or adding one to ten aminoacid residue and passing RAS/MAPK signal channel path to take mitosis. Interfusing albumen of the polypeptide and the out area of the rat resource erythropoietin has one sequence of the following aminoacid residue: SEQ ID No:2, the albumen relative to cell transferring of SEQ ID No:1 that has been replaced and/or lacking and/or adding one to ten aminoacid residue and passing RAS/MAPK signal channel path to take mitosis. It has great actual value and wide application prospect.

Provided herein are nanoparticles comprising antisense-encoded erythropoietin receptor (RopE) alone or in combination with erythropoietin receptor (EpoR). Also provided herein are methods of treating or preventing lungs disorders comprising administering RopE alone or in combination with EpoR.